CL2019001918A1 - Métodos para tratar infecciones bacterianas. - Google Patents

Métodos para tratar infecciones bacterianas.

Info

Publication number
CL2019001918A1
CL2019001918A1 CL2019001918A CL2019001918A CL2019001918A1 CL 2019001918 A1 CL2019001918 A1 CL 2019001918A1 CL 2019001918 A CL2019001918 A CL 2019001918A CL 2019001918 A CL2019001918 A CL 2019001918A CL 2019001918 A1 CL2019001918 A1 CL 2019001918A1
Authority
CL
Chile
Prior art keywords
methods
bacterial infections
treating bacterial
urinary tract
tract infection
Prior art date
Application number
CL2019001918A
Other languages
English (en)
Inventor
Jeffrey S Loutit
Michael N Dudley
Elizabeth E Morgan
Karen Fusaro
David C Griffith
Olga Lomovskaya
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of CL2019001918A1 publication Critical patent/CL2019001918A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EN LA PRESENTE SE DESCRIBEN MÉTODOS PARA TRATAR O MEJORAR UNA INFECCIÓN DEL TRACTO URINARIO (UTI), QUE INCLUYE INFECCIÓN DEL TRACTO URINARIO COMPLICADA (CUTI) Y PIELONEFRITIS AGUDA (AP), QUE COMPRENDEN ADMINISTRAR UNA COMPOSICIÓN QUE COMPRENDE UN ÉSTER DE ÁCIDO BORÓNICO CÍCLICO, VABORBACTAM, EN COMBINACIÓN CON MEROPENEM.
CL2019001918A 2017-01-09 2019-07-09 Métodos para tratar infecciones bacterianas. CL2019001918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01

Publications (1)

Publication Number Publication Date
CL2019001918A1 true CL2019001918A1 (es) 2020-02-14

Family

ID=62791302

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001918A CL2019001918A1 (es) 2017-01-09 2019-07-09 Métodos para tratar infecciones bacterianas.
CL2020001886A CL2020001886A1 (es) 2017-01-09 2020-07-17 Métodos para tratar infecciones bacterianas. (divisional solicitud 201901918)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001886A CL2020001886A1 (es) 2017-01-09 2020-07-17 Métodos para tratar infecciones bacterianas. (divisional solicitud 201901918)

Country Status (15)

Country Link
US (1) US20190336475A1 (es)
EP (2) EP4212157A1 (es)
JP (2) JP7436206B2 (es)
KR (1) KR20190104385A (es)
CN (1) CN110402139A (es)
AU (1) AU2018205327B2 (es)
BR (1) BR112019014089A2 (es)
CA (1) CA3048650A1 (es)
CL (2) CL2019001918A1 (es)
CO (1) CO2019008575A2 (es)
MX (2) MX2019008281A (es)
NZ (1) NZ755141A (es)
PH (1) PH12019501606A1 (es)
SG (1) SG11201906226YA (es)
WO (1) WO2018129479A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376237B2 (en) * 2017-10-03 2022-07-05 Melinta Subsidiary Corp. Methods of treating bacterial infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
WO2014186309A1 (en) * 2013-05-15 2014-11-20 Schaeffler Technologies Gmbh & Co. Kg Reduced drag clutch plate
JP6945452B2 (ja) 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法

Also Published As

Publication number Publication date
SG11201906226YA (en) 2019-08-27
PH12019501606A1 (en) 2020-06-15
CN110402139A (zh) 2019-11-01
JP2020504154A (ja) 2020-02-06
CL2020001886A1 (es) 2020-12-18
JP7436206B2 (ja) 2024-02-21
MX2022001704A (es) 2022-03-11
CO2019008575A2 (es) 2019-08-30
WO2018129479A1 (en) 2018-07-12
US20190336475A1 (en) 2019-11-07
KR20190104385A (ko) 2019-09-09
AU2018205327A1 (en) 2019-07-25
EP3565551B1 (en) 2024-03-20
MX2019008281A (es) 2019-12-02
EP3565551A4 (en) 2020-09-23
EP4212157A1 (en) 2023-07-19
NZ755141A (en) 2023-01-27
EP3565551A1 (en) 2019-11-13
BR112019014089A2 (pt) 2020-02-04
JP2023012538A (ja) 2023-01-25
CA3048650A1 (en) 2018-07-12
AU2018205327B2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2016009898A (es) Tratamientos para acne resistente.
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
MX2020013468A (es) Anticuerpos il-11ra.
TW201613575A (en) Treatment of polybacterial infections
BR112015013123A2 (pt) inibidores de beta-lactamase
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX2018002067A (es) Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
ECSP088634A (es) Metodos para tratar infecciones del tracto gastrointestinal con tigeciclina
ZA202006612B (en) Antibacterial compounds
ZA202002093B (en) Antibacterial compounds
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
EA201791051A1 (ru) Способ лечения, профилактики или снижения риска возникновения кожной инфекции
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
IN2013MU03216A (es)
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
AR104200A1 (es) Carboximetilcisteina para tratamiento tópico de estrías
EA201591267A1 (ru) Рифаксимин для применения в лечении вагинальных инфекций
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos
RU2014125665A (ru) Способ наружного лечения микозов кожи